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Background: The inflammatory bowel disease (IBD) disability index has recently been introduced to measure patients’ physical, psychological, familial, and
social limitations associated with IBD. We assessed factors related to self-reported disability and the relationship between disability and direct health care costs.
Methods: A large cohort of patients with Crohn’s disease (CD) and ulcerative colitis (UC) was prospectively followed for 2 years by 3 monthly web-
based questionnaires. At 2 years, patients completed the IBD disability index, with lower score indicating more disability. Linear regression analysis was
used to examine the impact of demographics, clinical characteristics, and illness perceptions on self-reported disability. Trends in direct health care costs
across the disability severity groups minimal, mild, moderate, and severe, were tested.
Results: A total of 554 patients with CD and 424 patients with UC completed the IBD disability index (response rate, 45%). Both clinical characteristics
and illness perceptions significantly contributed to self-reported disability (45%–47%, P ¼ 0.000 and 8%–12%, P ¼ 0.000, respectively). Patients
with CD scored lower on the self-reported IBD disability index than patients with UC (0.255 versus 3.890, P , 0.000), indicating more disability in
patients with CD. Factors independently associated with higher self-reported disability rates were increased disease activity, illness identity (higher
number of symptoms attributed to IBD), and stronger emotional response. Disease duration and disease phenotype were not associated with self-reported
disability. Direct health care costs increased with the worsening of self-reported disability (P ¼ 0.000).
Conclusions: More disability was reported by patients with CD than by UC. Self-reported disability in IBD was mainly determined by clinical disease
activity and illness perceptions but not by disease duration or disease phenotype.
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T he natural history of Crohn’s disease (CD) and ulcerativecolitis (UC) is characterized by periods of relapse and remis-
sion, potentially leading to intestinal damage, and surgery over
time.1,2 This may induce a wide spectrum of physical, psycholog-
ical, familial, and social problems.3,4 Both widely used symptom-
assessment tools and quality of life (QOL) questionnaires cannot
provide a reliable assessment of these problems.5,6 Therefore,
Peyrin-Biroulet et al recently developed the inflammatory bowel
disease (IBD) disability index to objectively and comprehensively
cover the range of functional limitations in IBD.7 This tool is
thought to be useful for clinical practice, disease modification
trials, and health reporting in IBD.7,8
The IBD disability index is based on the WHO’s Interna-
tional Classification of Functioning, Health, and Disability.9 This
classification describes the impact of illness on a patient as
a dynamic interaction between illness, personal, and environmen-
tal factors. Functioning is subdivided into the activity and the
participation component, including regulating defecation, inter-
personal activities, and work. The health-related component con-
sists of body structures, such as blood in stool and arthritis/
arthralgia, and body functions, such as energy, sleep, and body
image. Personal and environmental factors are recognized as
mediating factors for the association between these 2 components.
Important mediating factors are the patient’s illness percep-
tions. According to the Common Sense Model,10 these illness
perceptions or patient beliefs may attenuate the impact of clinical
characteristics on clinical outcomes, including disability, QOL,
and distress.11–13
In contrast to other chronic illnesses, such as rheumatoid
arthritis,14 data on disability in IBD are scarce. Most studies in
IBD on this topic have a retrospective design,15,16 are small, or are
focused on work disability.17,18 In a prospective validation study
of 166 participants, the interview-based IBD disability index has
been reported to be reliable, reproducible, sensitive for detecting
disability, with a good correlation with the Crohn’s Disease
Activity Index, Mayo index, and Inflammatory Bowel Disease
Questionnaire.19
This study aimed to assess: (1) the severity of self-reported
disability and functional limitations, (2) determinants of self-
reported disability, (3) the impact of self-reported disability on
direct health care costs (DHC) and QOL in a nationwide cohort of
patients with IBD.
METHODS
Patient Population and Study Design
The Costs Of Inflammatory bowel disease In the Netherlands
(“COIN”) cohort was established in 2010. This is an ongoing
study of adult patients with CD and UC from 7 general and 8
university hospitals in the Netherlands who were identified between
2007 and 2010, using Diagnosis-Treatment-Combination codes.
Patients completed 3 monthly web-based questionnaires including
questions about demographics, clinical characteristics, and resource
utilization. The cohort is described in more detail in a previous
report.20 The study was centrally approved by the Ethics Committee
of the University Medical Center Utrecht, Utrecht.
The primary outcome of interest, self-reported disability
(hereafter referred to as “disability”), was measured with the IBD
disability index 24 months after study entry. Most information on
demographic and clinical and behavioral determinants of disabil-
ity was collected concurrently. Data concerning smoking, educa-
tion, comorbid conditions, and disease localization were assessed
at baseline. Of the 3015 patients who were included in the COIN
study, 505 (17%) were lost to follow-up. Patients who were lost to
follow-up were more likely to be female (P ¼ 0.021), smoker
(P ¼ 0.000), and had a lower education level (P ¼ 0.000) than
those patients with IBD who were not lost to follow-up.
Determinants
Determinants of disability were based on previous studies on
factors independently associated with work disability or a disabling
disease course, encompassing stricturing or penetrating disease,
requiring abdominal surgery or immunomodulators (see Table,
Supplemental Digital Content 1, http://links.lww.com/IBD/A674).
Demographic determinants included gender, age, smoking
status (current smoker, exsmoker, nonsmoker), and education level
(low versus high). Low education included no education, primary
education, secondary education, and technical or professional
school, whereas high education included higher vocational educa-
tion and university.
Clinical determinants included comorbid conditions (self-
reported depression, joint complaints, chronic back pain), age at
diagnosis, disease duration, localization at enrollment for CD (ileal,
colonic, ileocolonic), penetrating disease course for CD (defined as
perianal fistula or other fistula), previous IBD-related surgery, stoma,
pouch, and medical treatment at enrollment (mesalazine, cortico-
steroids, immunomodulators, anti-TNF agents). Previous IBD-related
surgery compromised intestinal resections and perianal operations.
Behavioral determinants included illness perceptions, which
were assessed with the Brief Illness Perception Questionnaire.21
This 9-item questionnaire explores the cognitive and emotional
representations of illness across 8 dimensions: Consequences,
Timeline, Personal Control, Treatment Control, Identity, Concerns,
Understanding, and Emotional Response. Items are assessed on an
11-point Likert scale; e.g., “How much does your illness affect your
life?”: 0 [“not at all”]–10 [“severely affects my life”].
IBD Disability Index
The IBD disability index consists of 28 questions, exploring
limitations across 5 International Classification of Functioning,
Health, and Disability domains: Overall Health, Body Functions
(sleep/energy, affect, body image, pain, diarrhea, body mass index,
weight loss), Activities and Participation (regulating defecation,
looking after one’s health, interpersonal activities, and work/edu-
cation), Body Structures (blood in stool, arthralgia/arthritis), and
Environmental Factors (exacerbating effect of medication, food,
family, and health care professional).7
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A validated scoring system was used to measure the presence
and severity of disability in the previous week with lower or
negative scores indicating greater disability (see Data, Supplemen-
tal Digital Content 2, http://links.lww.com/IBD/A675).19 The total
score on the IBD disability index ranges between 280 (maximum
degree of disability) and 22 (no disability). The severity of disabil-
ity was categorized into minimal (.210), mild (210 to 219),
moderate (220 to 235), and severe (#235).19 The majority of
questions are scored by patients on a 5-point Likert scale (“no,”
“mild,” “moderate,” “severe or extreme limitations”), whereas other
questions included a dichotomous answer (“yes” or “no”).
DHC and QOL
DHC included costs related to outpatient hospital visits,
diagnostic procedures medication use, stoma appliance use, IBD-
related hospitalizations, and IBD-related surgeries. DHC were
calculated by multiplying self-reported units of resource utiliza-
tion by their unit costs.22
QOL was measured by the validated Dutch translation of
the Inflammatory Bowel Disease Questionnaire-32, encompassing
32 items, with a graded response range of “worst” (1) to “best” (7)
and a possible total score of 32 to 224.6,23
Statistical Analysis
Data analyses were performed using SPSS 20.0 and SAS
9.2. Descriptive statistics were used to characterize patients with
CD and UC. Means and medians were reported with a SD and
interquartile range, respectively. Comparisons between CD and UC
were analyzed with Student’s t test for continuous variables and x2
or Fisher’s exact test for dichotomous variables. The IBD disability
index was translated into the self-reported IBD disability index by 4
authors (B.O., H.H.F., A.A.K., M.H.), following the forward-
backward-forward technique. Two randomly selected groups of
10 outpatients with IBD filled out the self-reported IBD disability
index, followed 1 week later by an interview-based IBD disability
index (group 1) or vice versa (group 2). The reproducibility of the
IBD disability index was assessed with the reliability coefficient by
Bland and Altman.24 Correlation analyses were performed to assess
associations between demographic, clinical and behavioral determi-
nants, and the IBD disability score (see Table, Supplemental Digital
Content 3, http://links.lww.com/IBD/A678). Variables that reached
at least a borderline statistical significance (P , 0.10) in the cor-
relation analyses were included in the hierarchical linear regression
analysis, which is based on the Common Sense Model.10 Tests for
trends in DHC across the categories minimal, mild, moderate, and
severe disability were conducted by using the median value in each
category as a continuous variable in the linear regression models.
RESULTS
Patient Population
In total, 1108 patients with IBD (response rate: 45%) were
enrolled, including 554 patients with CD (50%), 424 patients with
UC (38%), and 130 patients with “IBD-unknown/unclassified”
(12%) (Fig. 1). Patients with “IBD-unknown/unclassified” were
excluded from further analyses.
Table, Supplemental Digital Content 4, http://links.lww.com/
IBD/A676 shows data on baseline demographic and clinical char-
acteristics in both the responders (CD: n ¼ 554 and UC: n ¼ 424)
and nonresponders (CD: n¼ 726 and UC: n¼ 479). There were no
relevant statistical significant differences between both groups.
Patients with CD were more likely to be female (58%
versus 45%, P ¼ 0.000), smoker (20% versus 7%, P ¼ 0.000),
had a lower age at diagnosis (30.7 versus 36.0 yr, P ¼ 0.000),
a higher probability of having a stoma (14% versus 5%), and
a lower probability of having a pouch (2% versus 9%, P ¼
0.000) as compared with patients with UC. Patients with CD were
more frequently treated with immunomodulators (31% versus
21%, P ¼ 0.000) and/or anti-TNF agents (21% versus 4%, P ¼
0.000) as compared with patients with UC.
Self-reported IBD Disability Index: Internal
Consistency, Reproducibility
The internal consistency/reproducibility (Cronbach’s a) for
the 5-point Likert questions was 0.872. The total scores showed
a good reproducibility between the patient-reported and
interview-based IBD disability index, with a 95% probability that
the total score on the second IBD disability index fell within the
Bland and Altman coefficient of repeatability. Reproducibility
was comparable for group 1 and group 2.
Severity of Disability and
Functional Limitations
Patients with CD scored significantly lower on the self-
reported IBD disability index as compared with patients with UC
FIGURE 1. Study flow-chart.
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(0.255 versus 3.890, P , 0.000), indicating a greater disability
in CD. Problems that were most frequently reported by both CD
and UC patients were related to sleep and abdominal pain (Fig. 2).
Patients with CD reported significantly more problems related to
abdominal pain (55% versus 44%, P ¼ 0.022), regulating
defecation (43% versus 30%, P ¼ 0.027), looking after one’s
health (45% versus 38%, P ¼ 0.000), participation in the com-
munity (42% versus 29%, P ¼ 0.000), personal relationships
(33% versus 25%, P ¼ 0.005), and work (50% versus 35%,
P ¼ 0.000) as compared with patients with UC.
FIGURE 2. Functional limitations in patients with CD (n ¼ 554) and UC (n ¼ 424). †Patients with CD (333) and UC (274) were used or partially
disabled. ††Patients with CD (20) and UC (10) were student. *P , 0.05; **P , 0.01; ***P , 0.001.
FIGURE 3. Percentages of variance in self-reported disability total and domain subscores by demographic (step 1), clinical (step 2), and behavioral
variables (step 3) in patients with CD (n ¼ 554).
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Determinants of Disability
Multiple hierarchical regression analyses were performed
to assess the contributory role of demographic (step 1), clinical
(step 2), and behavioral (e.g., illness perceptions) determinants
(step 3) in determining the IBD disability index total and its
domain subscores. In patients with CD, demographic, clinical,
and behavioral determinants contributed towards a significant
proportion of explained variance in total IBD disability score,
namely 1.0% (P , 0.05), 44.7% (P , 0.001), and 12.0% (P ,
0.001), respectively (Fig. 3). Factors that were independently
associated with greater disability included clinical disease activ-
ity (b ¼ 25.696; 95% CI, 28.763 to 22.629), previous
CD-related surgery (b ¼ 2.279; 95% CI, 0.647–3.912),
self-reported depression (b ¼ 25.696; 95% CI, 28.763 to
22.629), and the illness perceptions Personal Control (b ¼
0.354; 95% CI, 0.047–0.661), identity (b 20.940; 95% CI,
21.464 to 20.416), and Emotional response (b ¼ 20.522;
95% CI, 20.949 to 20.094) (Table 2). In patients with UC,
demographic, clinical, and behavioral determinants contributed
towards a significant proportion of explained variance in total
IBD disability score, namely 4.2% (P , 0.001), 46.8% (P ,
0.001), and 7.5% (P , 0.001), respectively (Fig. 4). Factors that
were independently associated with greater disability included
clinical disease activity (b ¼ 22.891; 95% CI, 23.385 to
22.396) and the illness perceptions Identity (b ¼ 20.643;
95% CI, 21.218 to 20.067), and Emotional response (b ¼
20.497; 95% CI, 20.926 to 20.068) (Table 2).
Relationship Between Mean DHC, QOL, and
Self-reported IBD Disability Severity
Of the total 1108 patients with IBD, minimal, mild,
moderate, and severe disability were present in 901 (81.3%), 129
(11.6%), 70 (6.3%) and 8 (0.7%) patients, respectively (see Fig.,
Supplemental Digital Content 5, http://links.lww.com/IBD/A677).
A statistically significant increasing linear trend (P ¼ 0.000) in
DHC as disability increased was demonstrated. In addition, a statis-
tically significant decreasing linear trend (P ¼ 0.000) in mean QOL
scores as disability increased was demonstrated.
DISCUSSION
In this Dutch nationwide cohort, we observed that disability
was mainly determined by clinical disease activity and illness
perceptions. Typical characteristics of a complicated disease
course, including disease duration, penetrating disease, ileal
involvement, or surgery, were not associated with disability.
Additionally, we found that greater disability was associated with
higher DHC and a lower QOL.
FIGURE 4. Percentages of variance in self-reported disability and domain subscores by demographic (step 1), clinical (step 2), and behavioral
variables (step 3) in patients with UC (n ¼ 424).
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To our knowledge, this is the largest study to date,
assessing functional disability in patients with IBD with the
recently introduced IBD disability index. This index has pre-
viously demonstrated to be reliable, reproducible, and sensitive
for detecting disability.19 It has also shown to have a good corre-
lation with existing symptom-assessment tools and with the
Inflammatory Bowel Disease Questionnaire. However, as the
IBD disability index needs to be completed by a physician, im-
plementation into clinical practice is challenging. Therefore, we
studied the agreement between the patient-reported and interview-
based IBD disability index and found a good reproducibility
(repeatability coefficient $0.95) between these 2 indices.
It seems plausible that a complicated disease course in
IBD—characterized by strictures, fistulas, and surgeries—leads
to intestinal dysfunction, surgery, and a progressive deteriora-
tion of the functional status.25 Yet, in line with previous stud-
ies,15,26 we found that disability was mainly determined by
clinical disease activity and illness perceptions but not by char-
acteristics of a complicated disease course.
In a small pilot study of 38 patients with IBD, it has been
found that perceived disability (as measured with the Perceived
Disability Scale) was moderately to strongly associated with
bowel health, systemic health, more abdominal pain, less
engagement in daily activities, higher perceived stress, and
a higher number of gastroenterologist visits.15 Perceived disability
was not significantly associated with disease duration, hospital-
izations, and history of surgeries. In a recent study among 244
patients with long-term IBD from the population-based Manitoba
Cohort study, it has been found that disability (as measured with
World Health Organization Disability Assessment Schedule) was
associated with long-term clinical disease activity and a history of
major depression but not with disease duration, previous IBD
surgeries, or disease phenotype.26
In addition, we found that disability was strongly associ-
ated with several illness perceptions. Illness perceptions
accounted for 1% to 13% of the explained variance in disability,
in addition to demographic (1%–5%) and clinical characteristics
(13%–47%). This finding is in line with the results of a previous
study that showed that illness perceptions accounted for 23% of
the explained variance in disability (as measured with the Func-
tional Limitations Profile), in addition to demographic variables
(23%) and coping (6%).16 Our findings corroborate the Common
Sense Model, in which it is stated that individual’s personal
beliefs about IBD play a major role in the adjustment to the
illness.10,27
In both CD and UC patients, illness identity was strongly and
independently associated with disability. This indicates that patients
with IBD who associate a wide range of symptoms to their illness
experience a greater disability. It has been postulated that patients
misattribute unrelated symptoms to IBD, leading to a perception of
greater disease activity and subsequently to disability.10 Our find-
ings are in line with previous studies in IBD and other immune-
mediated inflammatory diseases demonstrating illness identity to be
strongly associated with increased disability (IBD16; RA11,28 and
psoriasis12,28), reduced QOL (IBD29,30; RA28 and psoriasis12), and
psychological distress (RA31). Emotional response was also
strongly and independently associated with disability in patients
with CD and UC. The latter finding concurs with previous studies
in patients with IBD15,29,30 and indicates that negative beliefs about
the effects of illness on the patient’s emotional status (in terms of
anxiety and depression) result in the perception of a greater
disability.
Personal control was strongly and independently associated
with disability in patients with CD but not in UC. This suggests
that patients with CD with less personal controllability of their
illness experience a greater disability. The fact that personal
controllability was not statistically significantly associated with
disability in UC might be explained by the fact that patients with
CD were more likely to have a stoma. Patients with a stoma can
be expected to have specific problems and concerns, such as
leakage, and inability to control gas, which may compromise their
TABLE 1. Demographic and Clinical Characteristics of
the Study Population
CD (n ¼ 554) UC (n ¼ 424) P
Demographic characteristics
Male gender (%) 232 (42) 234 (55) 0.000
Age (6SD), yr 55.0 (13.4) 56.4 (12.6) 0.100
Current smoker (%) 108 (20) 28 (7) 0.000
Low education (%) 345 (62) 232 (55) 0.114
Clinical characteristics
Comorbid conditions (%)
Depression 46 (8) 31 (7) 0.789
Joint complaints 160 (28) 91 (21) 0.030
Chronic back pain 59 (11) 37 (9) 0.316
Age at diagnosis (6SD), yr 30.7 (12.7) 36.0 (13.5) 0.000
Disease duration, median
(IQR)
19.5 (10.5–31.5) 16.5 (9.5–24.2) 0.000
Disease localization (%)
Large bowel 165 (30)
Small bowel 119 (22)









313 (57) 74 (18) 0.000
Stoma (%) 76 (14) 21 (5) 0.000
Pouch (%) 13 (2) 40 (9) 0.000
Medication use (%)
Mesalazine 131 (24) 281 (66) 0.000
Steroids 47 (9) 27 (6) 0.225
Immunosuppressant 170 (31) 87 (21) 0.000
Anti-TNFa agents 115 (21) 15 (4) 0.000
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control over the illness.32 It may also be possible that the impact
of personal control on disability in UC is canceled out by other
factors, including the relapse rate. In our cohort, the relapse rate
during 2 years of follow-up was significantly higher in patients
with UC compared with CD (data not shown).
Finally, we have demonstrated that mean DHC increased and
mean QOL scores decreased significantly with increasing of
disability in patients with IBD. These findings strongly suggest
that preventing disability in IBD may be a useful strategy to reduce
future direct and indirect health care costs and burden to society.
This study has several strengths. First, the self-reported IBD
disability index showed a good reliability and agreement with the
interview-based disability index. Therefore, the self-reported IBD
disability index can be used in web-based questionnaires, which
may facilitate clinical research. Second, the large sample size
enabled us to assess a large panel of potential determinants of
disability. Third, patients were included from both university and
general hospitals, thereby in our view, reliably representing the
average patient with IBD in the Netherlands.
Several limitations of this study need to be addressed as
well. First, an inherent limitation to the web-based design of this
study is sampling bias. Although one might assume that disabled
patients are more willing to fill out the questionnaires, we did not
observe statistically significant differences between responders
and nonresponders regarding relevant demographics, disease
characteristics, and DHC. Second, self-reported data on comorbid
conditions (e.g., depression) may be inaccurate. Third, potential
determinants of functional disability, including endoscopic and
laboratory markers of disease activity (CRP, fecal calprotectin),
were not available. Fourth, as we performed a cross-sectional
analysis, correlations between demographic, clinical, and behav-
ioral variables and disability do not imply causality. For example,
the inverse correlation that was found between anti-TNF treatment
and disability may be caused by confounding by indication. Fifth,
although we assessed the agreement between the patient-reported
and interview-based IBD disability index, additional studies are
required to determine the construct validity, discriminant ability,
test–retest reliability, and responsiveness of the patient-reported
IBD disability index.
Our findings underscore the importance of addressing and
understanding patients’ symptoms and perceptions of IBD. This
relevant information allows clinicians to guide counseling and
tailoring medical and biopsychosocial interventions to a patient’s
specific needs, potentially resulting in less disability, lower health
care costs and a higher QOL. Previous studies have already shown
that behavioral interventions based on the Common Sense Model
of self-regulation can change illness perceptions of patients after
myocardial infarction and patients with end-stage renal disease
and thereby improve major components of QOL (i.e., return to
work).33,34
TABLE 2. Independent Determinants of Self-reported Disability in Patients with CD (n ¼ 554) and UC (n ¼ 424)
CD UC
b 95% CI P b 95% CI P
Demographics
Gender 0.938 20.669 to 2.545 0.252 20.399 22.000 to 1.202 0.625
Current smoker 0.688 21.314 to 2.690 0.500 23.019 26.101 to 0.064 0.055
Clinical determinants
Age at diagnosis 20.006 20.071 to 0.058 0.847
Clinical disease activity 25.696 28.763 to 22.629 0.000 22.891 23.385 to 22.396 0.000
Previous CD-related surgery 2.279 0.647 to 3.912 0.006
Pouch 1.887 23.492 to 7.265 0.491
Depression 25.696 28.763 to 22.629 0.000 20.440 23.505 to 2.624 0.778
Back pain 0.206 22.473 to 2.885 0.880
Arthralgia 20.622 22.481 to 1.237 0.511 20.895 22.883 to 1.093 0.377
Steroids 20.142 23.343 to 3.059 0.930
Anti-TNF agents 0.015 21.822 to 1.851 0.987 0.139 24.291 to 4.570 0.951
Illness perceptions
Consequences 20.401 20.862 to 0.06 0.088 20.399 20.894 to 0.097 0.114
Personal control 0.354 0.047 to 0.661 0.024 0.155 20.135 to 0.444 0.294
Treatment control 0.171 20.135 to 0.477 0.273 0.274 20.046 to 0.594 0.094
Identity 20.940 21.464 to 20.416 0.000 20.643 21.218 to 20.067 0.029
Concerns 20.420 20.855 to 0.016 0.059 20.160 20.623 to 0.302 0.496
Understanding 0.0450 20.300 to 0.389 0.799 20.004 20.337 to 0.329 0.981
Emotional response 20.522 20.949 to 20.094 0.017 20.497 20.926 to 20.068 0.023
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In conclusion, our results clearly show that disability in IBD
is associated with clinical disease activity and illness perceptions
but not with a longer disease duration or an unfavorable disease
phenotype. Greater disability is associated with higher costs and
lower QOL. Because illness perceptions are potentially modifiable
factors, they may provide a relevant target for interventions aimed
at improving disability and other health outcomes. Future studies
should focus on the additional value of the IBD disability compared
with current symptom-assessment tools.
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